Although programmed death ligand-1(PD-L1) has been established as a biomarker for immune checkpoint inhibitors (ICIs) in HNSCC, its limitations have been recognized, as some PD-L1-negative patients still derive benefit from ICIs [6]. Here, CD274 is linked to head and neck squamous cell carcinoma.